VEA
Virtus ETF Advisers Portfolio holdings
AUM
$75.7M
1-Year Return
23.01%
This Quarter Return
+10.73%
1 Year Return
+23.01%
3 Year Return
+79.79%
5 Year Return
+153.94%
10 Year Return
–
AUM
$188M
AUM Growth
+$30.7M
(+19%)
Cap. Flow
+$19.9M
Cap. Flow
% of AUM
10.59%
Top 10 Holdings %
Top 10 Hldgs %
6.1%
Holding
495
New
69
Increased
189
Reduced
162
Closed
73
Top Buys
| 1 |
Palantir
PLTR
|
$1.01M |
| 2 |
BlackRock TCP Capital
TCPC
|
$1M |
| 3 |
Host Hotels & Resorts
HST
|
$993K |
| 4 |
DFS
Discover Financial Services
DFS
|
$989K |
| 5 |
Public Storage
PSA
|
$931K |
Top Sells
| 1 |
Burlington
BURL
|
$962K |
| 2 |
Prologis
PLD
|
$773K |
| 3 |
Booking.com
BKNG
|
$734K |
| 4 |
Eaton
ETN
|
$720K |
| 5 |
TE Connectivity
TEL
|
$708K |
Sector Composition
| 1 | Healthcare | 21.52% |
| 2 | Financials | 20.16% |
| 3 | Technology | 16.46% |
| 4 | Industrials | 8.76% |
| 5 | Energy | 7.14% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
INBX
351
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $110K | 0.06% |
3,143
-219
| -7% | -$7.66K |
|
|
ITOS
352
DELISTED
iTeos Therapeutics
ITOS
| $110K | 0.06% |
8,046
-550
| -6% | -$7.5K |
|
353
Ardelyx
ARDX
$1.57B
| $109K | 0.06% |
14,940
-1,022
| -6% | -$7.46K |
|
354
Revolution Medicines
RVMD
$7.57B
| $107K | 0.06% |
3,311
-229
| -6% | -$7.38K |
|
355
Arcturus Therapeutics
ARCT
$485M
| $104K | 0.06% |
3,087
-215
| -7% | -$7.26K |
|
356
Syndax Pharmaceuticals
SNDX
$1.47B
| $104K | 0.06% |
4,359
-298
| -6% | -$7.09K |
|
|
MORF
357
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $103K | 0.05% |
2,935
-198
| -6% | -$6.97K |
|
358
Phathom Pharmaceuticals
PHAT
$875M
| $103K | 0.05% |
9,701
-666
| -6% | -$7.07K |
|
359
AnaptysBio
ANAB
$613M
| $102K | 0.05% |
4,551
-311
| -6% | -$7K |
|
360
Zymeworks
ZYME
$1.14B
| $101K | 0.05% |
9,605
-659
| -6% | -$6.93K |
|
361
Celldex Therapeutics
CLDX
$1.52B
| $101K | 0.05% |
2,399
-162
| -6% | -$6.8K |
|
362
Day One Biopharmaceuticals
DAWN
$773M
| $100K | 0.05% |
6,078
-414
| -6% | -$6.84K |
|
363
Arvinas
ARVN
$575M
| $100K | 0.05% |
2,431
-164
| -6% | -$6.77K |
|
364
Precigen
PGEN
$1.3B
| $99.7K | 0.05% |
68,764
-4,713
| -6% | -$6.83K |
|
365
Soleno Therapeutics
SLNO
$3.71B
| $99.6K | 0.05% |
2,327
-163
| -7% | -$6.98K |
|
366
Madrigal Pharmaceuticals
MDGL
$9.65B
| $98.3K | 0.05% |
368
-29
| -7% | -$7.74K |
|
367
Akero Therapeutics
AKRO
$3.58B
| $98K | 0.05% |
3,879
-269
| -6% | -$6.8K |
|
368
Vaxcyte
PCVX
$4.29B
| $97.8K | 0.05% |
1,432
-96
| -6% | -$6.56K |
|
369
Beam Therapeutics
BEAM
$2.11B
| $96.2K | 0.05% |
2,911
-197
| -6% | -$6.51K |
|
370
Lyell Immunopharma
LYEL
$233M
| $95.6K | 0.05% |
2,145
-147
| -6% | -$6.56K |
|
371
89bio
ETNB
$1.32B
| $93.6K | 0.05% |
8,038
-550
| -6% | -$6.4K |
|
|
CMPS
372
Compass Pathways
CMPS
$493M
| $93.4K | 0.05% |
11,221
-771
| -6% | -$6.42K |
|
373
Immatics
IMTX
$761M
| $92.9K | 0.05% |
8,837
-610
| -6% | -$6.41K |
|
374
Arcus Biosciences
RCUS
$1.3B
| $92.7K | 0.05% |
4,911
-340
| -6% | -$6.42K |
|
375
Disc Medicine
IRON
$2.11B
| $92.6K | 0.05% |
1,488
-101
| -6% | -$6.29K |
|